Zogenix Provides Corporate Update and Reports Second Quarter 2019 Financial Results Agreement reached with U.S. FDA for resubmission of NDA for FINTEPLA® for the treatment of Dravet syndrome; resubmission expected in SeptemberEnrollment complete for FINTEPLA global Phase 3 trial in...

Zogenix to Release Second Quarter 2019 Financial Results and Host Conference Call and Webcast on August 6 EMERYVILLE, Calif., July 30, 2019 (GLOBE NEWSWIRE) -- Zogenix, Inc. (NASDAQ: ZGNX), a global pharmaceutical company developing rare disease therapies, today announced that it will report its...